Advances in Molecular Diagnosis and Personalized Treatment of Soft Tissue Sarcomas
Published: 2024-11-07
Page: 239-259
Issue: 2024 - Volume 7 [Issue 2]
Gamal Abdul Hamid *
Faculty of Medicine, University of Aden, Yemen.
Fadhel Hariri
Ministry of Public Health, Supreme Board of Drugs and Medical Appliances, Aden, Yemen.
Mauro Luisetto
IMA Academy, Mariinskaya A, PC Area, Italy.
*Author to whom correspondence should be addressed.
Abstract
Soft tissue tumors are a diverse range of diagnostic entities including the majority of them benign in nature and behavior. Soft tissue sarcomas are uncommon tumors that represent 1% of all malignancies and are classified as malignant entities. The wide variety of tumor types and pathological overlap across the tumor entities make the diagnosis of soft tissue tumors difficult for pathologists. With the advancement of molecular genetic tools, our understanding of the molecular pathogenesis of soft tissue tumors has been significantly important in diagnosis, treatment, and prognosis. The role of surgery, chemotherapy, radiotherapy, target therapy, and immunotherapy are needed to identify patients who benefit from each type of treatment.
This review aims to provide an update on recently described diagnostic methods and management of soft tissue sarcomas.
Keywords: Soft tissue tumor, sarcoma, molecular pathology, immunohistochemistry, target therapy, immunotherapy